导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.70% | 3159/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -2.32% | 1240/5421 |
| 近一季 | -3.53% | 1426/5209 |
| 近半年 | -2.26% | 1840/4920 |
| 近一年 | -1.74% | 2914/4366 |
| 近两年 | 46.61% | 1588/2954 |
| 近三年 | 30.42% | 1040/2253 |
| 成立以来 | 49.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.22% 3786/4961 |
6.00% 2860/5312 |
- - |
- - |
| 2025 | 24.18% 1805/4813 |
3.35% 1105/3635 |
3.38% 1031/4076 |
15.13% 2842/4524 |
0.95% 1643/4813 |
| 2024 | 17.96% 633/3463 |
0.86% 931/2808 |
2.47% 349/3014 |
16.21% 1508/3129 |
-1.79% 1832/3463 |
| 2023 | -10.32% 1288/2656 |
1.00% 1661/2280 |
-4.73% 1267/2385 |
-0.08% 402/2515 |
-6.73% 1897/2655 |
| 2022 | -14.44% 371/2207 |
-10.02% 373/1919 |
6.89% 580/2016 |
-14.67% 1131/2113 |
4.26% 570/2208 |
| 2021 | -6.30% 1004/1822 |
-0.12% 331/1255 |
0.06% 1113/1330 |
-7.54% 1060/1466 |
1.40% 943/1822 |
| 2020 | 17.83% 757/1250 |
-11.06% 814/1028 |
9.33% 797/1067 |
5.84% 893/1164 |
14.50% 271/1184 |
| 2019 | 31.23% 474/1092 |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏上证50AH优选指数C VS. 长安沪深300非周期A(740101) |